THC Biomed Intl Ltd

Company Profile

THC Biomed Intl Ltd had its IPO on under the ticker symbol THCBF.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. THC Biomed Intl Ltd has a staff strength of 35 employees.

Stock update

Shares of THC Biomed Intl Ltd opened at $0.03 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.02 - $0.03, and closed at $0.03.

This is a +18.18% increase from the previous day's closing price.

A total volume of 27,700 shares were traded at the close of the day’s session.

In the last one week, shares of THC Biomed Intl Ltd have increased by +30%.

THC Biomed Intl Ltd's Key Ratios

THC Biomed Intl Ltd has a market cap of $4.35 million, indicating a price to book ratio of 0.7332 and a price to sales ratio of 1.3715.

In the last 12-months THC Biomed Intl Ltd’s revenue was $2.23 million with a gross profit of $-1029647 and an EBITDA of $-2992049. The EBITDA ratio measures THC Biomed Intl Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, THC Biomed Intl Ltd’s operating margin was -162.67% while its return on assets stood at -15.27% with a return of equity of -56.47%.

In Q1.3333333333333, THC Biomed Intl Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.1%.

THC Biomed Intl Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into THC Biomed Intl Ltd’s profitability.

THC Biomed Intl Ltd stock is trading at a EV to sales ratio of 1.9643 and a EV to EBITDA ratio of -4.0098. Its price to sales ratio in the trailing 12-months stood at 1.3715.

THC Biomed Intl Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$13.72 million

Total Liabilities

$8.05 million

Operating Cash Flow

$0

Capital Expenditure

$352

Dividend Payout Ratio

0%

THC Biomed Intl Ltd ended 2024 with $13.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $13.72 million while shareholder equity stood at $4.70 million.

THC Biomed Intl Ltd ended 2024 with $0 in deferred long-term liabilities, $8.05 million in other current liabilities, in common stock, $-27019011.00 in retained earnings and $0 in goodwill. Its cash balance stood at $205015.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $659304.00.

THC Biomed Intl Ltd’s total current assets stands at $3.31 million while long-term investments were $64000.00 and short-term investments were $0. Its net receivables were $109106.00 compared to accounts payable of $1.29 million and inventory worth $2.55 million.

In 2024, THC Biomed Intl Ltd's operating cash flow was $0 while its capital expenditure stood at $352.

Comparatively, THC Biomed Intl Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.03

52-Week High

$0.058

52-Week Low

$0.014

Analyst Target Price

$

THC Biomed Intl Ltd stock is currently trading at $0.03 per share. It touched a 52-week high of $0.058 and a 52-week low of $0.058. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.03 and 200-day moving average was $0.03 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 2902.8% of the company’s stock are held by insiders while 0% are held by institutions.